

5

**WHAT IS CLAIMED IS:**

1. A process for the treatment for restenosis comprising the intravascular infusion or delivery by release from the surface of a stent of combinations of at least two drugs to a patient in therapeutic dosage amounts.
2. The method of claim 1 wherein the combination of agents employed includes an anti-inflammatory agent and an antiproliferative agent.
3. The method of claim 2 wherein the anti-inflammatory agent is dexamethasone and the anti-proliferative agent is taken from the group of rapamycin, taxol, or vincristine.
4. The method of claim 1 wherein the combination of agents employed includes a growth factor or cytokine signal transduction inhibitor and an anti-proliferative agent.
5. The method of claim 4 wherein the signal transduction inhibitor is the ras inhibitor, R115777, and the anti-proliferative agent is taken from the group consisting of rapamycin, taxol, or vincristine.
6. The method of claim 1 wherein the combination of agents employed include a tyrosine kinase inhibitor and an anti-proliferative agent.
7. The method of claim 6 wherein the tyrosine kinase inhibitor is tyrphostin and the antiproliferative agent is taken from the group consisting of rapamycin, taxol, vincristine.

10

15

20

25

30

- 5
8. The method of claim 1 wherein the combination of agents employed includes an inhibitor of extracellular matrix synthesis and an antiproliferative agent.
- 10
9. The method of claim 8 wherein the anti-proliferative agent is taken from the group of rapamycin, taxol, or vincristine.
- 15
10. The method of claims 4 wherein the signal transduction inhibitor, the tyrosine kinase inhibitor or the extracellular matrix inhibitor is administered in combination with an anti-inflammatory inhibitor.
11. The method of claim 10 wherein the anti-inflammatory agent is dexamthasone.
- 20
12. In combination:  
a catheter for the delivery of drugs to a blood vessel lumen of a patient; and  
a therapeutic dosage amount of the combination of rapamycin and dexamethasone coated to or delivered through said catheter.
- 25
13. In combination:  
a stent for the delivery of drugs to a lumen of a patient; and  
a therapeutic dosage amount of rapamycin and dexamethasone coated to said stent.
- 30
14. A stent comprising:  
a plurality of struts, said struts expansible within the lumen of the body, and at least one of said struts containing a reservoir therein; and  
a therapeutic amount of rapamycin and dexamethasone coated to said stent.

claim 8

1. The first part of the document is a list of references. The references are listed in a standard format, with the author's name, the title of the work, and the publisher's name. The references are as follows:

1. The first part of the document is a list of references. The references are listed in a standard format, with the author's name, the title of the work, and the publisher's name. The references are as follows: